Last reviewed · How we verify
Sanqi+Bingpian
Sanqi+Bingpian is a traditional Chinese medicine compound that has been studied for its potential anti-inflammatory and cardiovascular protective effects.
Sanqi+Bingpian is a traditional Chinese medicine compound that has been studied for its potential anti-inflammatory and cardiovascular protective effects. Used for Angina pectoris.
At a glance
| Generic name | Sanqi+Bingpian |
|---|---|
| Sponsor | Tasly Pharmaceuticals, Inc. |
| Drug class | Traditional Chinese medicine compound |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
The exact mechanism of action of Sanqi+Bingpian is not fully understood, but it is believed to involve the inhibition of inflammatory pathways and the improvement of cardiovascular function through the modulation of various molecular targets.
Approved indications
- Angina pectoris
Common side effects
- Gastrointestinal upset
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sanqi+Bingpian CI brief — competitive landscape report
- Sanqi+Bingpian updates RSS · CI watch RSS
- Tasly Pharmaceuticals, Inc. portfolio CI